243 related articles for article (PubMed ID: 23342748)
1. [Nephrotic syndrome after treatment with d-penicillamine in a pediatric patient with Wilson's disease].
Farallo M; Amoruso C; Frattini C; Ardissino G; Nebbia G
Pediatr Med Chir; 2012; 34(5):234-6. PubMed ID: 23342748
[TBL] [Abstract][Full Text] [Related]
2. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
[TBL] [Abstract][Full Text] [Related]
3. Membranoproliferative glomerulonephritis in a patient with Wilson's disease.
Ozçakar ZB; Ekim M; Ensari A; Kuloglu Z; Yüksel S; Acar B; Kirsaçlioglu C; Kansu A; Yalçinkaya F; Girgin N
J Nephrol; 2006; 19(6):831-3. PubMed ID: 17173260
[TBL] [Abstract][Full Text] [Related]
4. [Nephrotic syndrome after treatment with penicillamine in Wilson's disease].
Hampel R; Meng W; Kallwellis G
Z Gesamte Inn Med; 1976 Jul; 31(13):507-11. PubMed ID: 960872
[TBL] [Abstract][Full Text] [Related]
5. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease.
Berger B; Mader I; Damjanovic K; Niesen WD; Stich O
Clin Neurol Neurosurg; 2014 Dec; 127():122-4. PubMed ID: 25459257
[No Abstract] [Full Text] [Related]
6. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
7. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
[TBL] [Abstract][Full Text] [Related]
8. Wilson's disease.
Walshe JM
Lancet; 2007 Mar; 369(9565):902. PubMed ID: 17368141
[No Abstract] [Full Text] [Related]
9. Penicillamine-induced lethal status dystonicus in a patient with Wilson's disease.
Svetel M; Sternić N; Pejović S; Kostić VS
Mov Disord; 2001 May; 16(3):568-9. PubMed ID: 11391761
[TBL] [Abstract][Full Text] [Related]
10. Management of penicillamine nephropathy in Wilson's disease: a new chelating agent.
Walshe JM
Lancet; 1969 Dec; 2(7635):1401-2. PubMed ID: 4188283
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
12. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha S; Taly AB
J Neurol Sci; 2008 Jan; 264(1-2):129-32. PubMed ID: 17765927
[TBL] [Abstract][Full Text] [Related]
14. Penicillamine induced pseudo-pseudoxanthoma elasticum in a patient with Wilson's disease, which role plays the hepatologist?
Ibáñez-Samaniego L; Ochoa-Palominos A; Catalina-Rodríguez MV; Salcedo-Plaza M; Clemente-Ricote G
Rev Esp Enferm Dig; 2015 Mar; 107(3):190-1. PubMed ID: 25733050
[No Abstract] [Full Text] [Related]
15. Neurologic deterioration in a child with Wilson's disease on penicillamine therapy.
Paul AC; Varkki S; Yohannan NB; Eapen CE; Chandy G; Raghupathy P
Indian J Gastroenterol; 2003; 22(3):104-5. PubMed ID: 12839386
[TBL] [Abstract][Full Text] [Related]
16. Nephrotic syndrome in the course of treatment of Wilson's disease with DL-penicillamine.
Karp M; Lurie M; Yonis Z
Arch Dis Child; 1966 Dec; 41(220):684-7. PubMed ID: 5927925
[No Abstract] [Full Text] [Related]
17. Concurrent massive breast enlargement, myasthenia gravis and dermopathy as manifestations of penicillamine toxicity in a Wilson's disease patient.
Tan SS; Latif SA; Poh WY
Med J Malaysia; 2012 Jun; 67(3):323-5. PubMed ID: 23082426
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of Wilson's disease: results of a single center experience.
Medici V; Trevisan CP; D'Incà R; Barollo M; Zancan L; Fagiuoli S; Martines D; Irato P; Sturniolo GC
J Clin Gastroenterol; 2006; 40(10):936-41. PubMed ID: 17063115
[TBL] [Abstract][Full Text] [Related]
19. [Long-term D-penicillamine therapy of Wilson's disease in childhood. Changes in blood coagulation and effects on the haematopoetic system].
Hayek HW; Schnack H; Widhalm S
Wien Klin Wochenschr; 1973 Feb; 85(8):122-5. PubMed ID: 4632215
[No Abstract] [Full Text] [Related]
20. Elastosis perforans serpiginosa in a patient with Wilson's disease.
Thwaites PA; Khan SA; Asadi K; Angus PW
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):144. PubMed ID: 28403984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
